2017 CPhI Japan ----- Product List

Sinoway Industrial Co.,Ltd

timg (1)(001).jpg2017 CPhI Japan - Product List1(002).jpg


Our Main Service

Custom Developing / Custom Manufacturing for APIs and key intermediates

Importing / Technology Transfer for Finish Dosage Form


Ⅱ Our Hot Items

i  "Me-too" new drugs developmentAPI advanced intermediates(Avoid current patent) ----Key intermediates for Sartan series, tatin series, Liptin series, Dipine Series, Tinib series etc.

ii  Polypeptide derivatives---Glatiramer,Liraglutide for R&D etc.

iii  Prostaglandin Derivatives---Cloprostenol Key intermediates etc.

iv  Multi-step synthesis skills including chiral compound( more than 15 steps ) and Scale-up in KG and Process Optimization.

v  PEG Chemistry: PEGylation drugs(4-Arm-PEG-Gyl-Irinotecan and PEG-Naloxone),PEG conjugates and proteins for long term controlled released drugs.

vi  Drug delivery system: Block copolymers and "proof-of-concept" for uses in DDS;(For example: Lipids)


Products under the patent are only for R&D use.

4.jpg


Products under the patent are only for R&D use.

Importing/Technology Transfer for Finish Dosage Form


5.jpg


Pharmaceutical Peptides

Product Name

CAS No.

Specification

Liraglutide Acetate

204656-20-2

99% up by HPLC,

S. Impurity<0.1% for R&D

Teriparatide Acetate

52232-67-4

98% up by HPLC

Glatiramer Acetate

147245-92-9

98% up for HPLC

Gonadorelin Acetate

34973-08-5

98% up by HPLC

Octreotide Acetate

83150-76-9

USP/EP

Oxytocin Acetate

50-56-6

98% up by HPLC

Eptifibatide Acetate

148031-34-9

USP/EP


Prostaglandin Derivatives

Product Name

CAS No.

Specification

Prostaglandin series

key Intermediates

32233-40-2;

70764-05-7;

99% up by HPLC

TravoprostIntermediates

54142-64-2;

208111-98-2 etc.

99% up by HPLC

Bimatoprost Intermediates

41162-19-0;

41639-74-1 etc.

99% up by HPLC

Latanoprost Intermediates

352276-28-9

41639-83-2 etc

99% up by HPLC

Cloprostenol Intermediates

54324-79-7

54713-44-9 etc

99% up by HPLC

Products under the patent are only for R&D use.


Pharmaceutical Intermediates

Product Name

CAS No.

Specification

Rosuvastatin calcium intermediates

147118-40-9;

147118-35-2 etc.

99% up by HPLC

S. Impurity<0.1%

Pitavastatin calcium intermediates

147511-70-4;

147489-06-3 etc.

99.5%up by HPLC

S. Impurity<0.1%

Sorafenib Intermediates

284462-37-9 etc.

99%up by HPLC

Febuxostat intermediates

160844-75-7 etc.

99%up by HPLC

Entecavir intermediate

1354715-15-3etc

99% up by HPLC

Solifenacin succinate intermediates

118864-75-8 etc.

99%up by HPLC

Rivaroxaban intermediates

446292-07-5 etc.

99%up by HPLC

1.3-Dichloro Acetone

534-07-6

99%up by HPLC

P-Hydroxybenzyl alcohol

623-05-2

99%up by HPLC

Products under the patent are only for R&D use.


APIs

Product Name

Quality

Developing Status

Nifuratel

99.9%up by HPLC

GMP,DMF preparation

Cinacalcet Hcl

99.9%up by HPLC

GMP,DMF

Azilsartan(Medoxomil)

99%up by HPLC

DMF,PMDA

Esomeprazole Magnesium dihydrate

99%up by HPLC

GMP application,

DMF; PMDA

Rabeprazole sodium

CP, JP

GMP, DMF, PMDA

Choline glycerophos phate (GPC)

99%up by HPLC

GMP application

DMF preparation

Pregabalin

99%up by HPLC

GMP,DMF,PMDA

Ezetimibe

99%up by HPLC

GMP,DMF,PMDA

Dabigatran Etexilate Mesylate

99%up by HPLC

GMP application,

DMF,PMDA

Palonosetron HCL

99%up by HPLC

GMP, DMF,PMDA

Vildagliptin

99%up by HPLC

R&D

Linagliptin

99%up by HPLC

R&D

Products under the patent are only for R&D use.


APIs

Product Name

Quality

Developing Status

Ibandronate Sodium hydrate

98.5%~101.5%

Single impurity≤0.10%

GMP,DMF

Dasatinib hydrate

99%up by HPLC

Single impurity≤0.10%

DMF,PMDA,

GMP application

Erlotinib hydrochloride

99%up by HPLC

Single impurity≤0.10%

DMF, PMDA,

GMP application

Bortezomib

99%up by HPLC

Single impurity≤0.10%

PMDA, DMF preparation,

Capecitabine

USP/EP

FDA,CEP,DMF

Lenalidomide

98.0%~102.0%

Single impurity≤0.10%

DMF, PMDA

FDA application,

Canagliflozin hemihydrate

Amorphous form

98.0%~102.0%

Single impurity≤0.10%

Under PV, DMF,PMDA

LCZ696

Assay of Valsartan49.8%~52.4%

Assay of Sacubitril   49.8%~52.4%

Single  impurity≤0.10%

Pilot scale, PMDA

DMF preparation,

Ticagrelor

99%up by HPLC

Single impurity≤0.10%

DMF,PMDA,

FDA application

Sofosbuvir

FormI, FormII, Amorphous

98.0%~102.0%

Single impurity≤0.10%

DMF, PMDA

Products under the patent are only for R&D use.